Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma

被引:11
|
作者
Machiraju, Devayani [1 ,2 ]
Schaefer, Sarah [3 ]
Hassel, Jessica C. [1 ,2 ]
机构
[1] Univ Hosp Heidelberg, Dept Dermatol, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Univ Heidelberg Hosp, Dept Dermatol, D-69120 Heidelberg, Germany
来源
LIFE-BASEL | 2021年 / 11卷 / 12期
关键词
age; melanoma; immunotherapy; tumor antigenicity; Tregs; gender; gut microbiome; stress; radiation; vaccination; IMMUNE CHECKPOINT INHIBITOR; CELL LUNG-CANCER; GUT MICROBIOTA; METASTATIC MELANOMA; DNA-DAMAGE; T-CELLS; COMBINATION THERAPY; CHOICE CHEMOTHERAPY; ANTITUMOR IMMUNITY; COMBINED NIVOLUMAB;
D O I
10.3390/life11121318
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected to benefit more from the treatment approach. However, in contrast to this hypothesis, recent studies in patients with metastatic melanoma have demonstrated that immunotherapy, especially with anti-PD1 treatment, is less effective in patients below 65 years, on average, with significantly lower responses and reduced overall survival compared to patients above 65 years of age. Besides, data on young patients are even more sparse. Hence, in this review, we will focus on age-dependent differences in the previously described resistance mechanisms to the treatment and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1 or PDL1 treatment in young melanoma patients.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
    Shui, Irene M.
    Scherrer, Emilie
    Frederickson, Andrew
    Li, Joyce W.
    Mynzhassarova, Anel
    Druyts, Eric
    Tawbi, Hussein
    MELANOMA RESEARCH, 2022, 32 (06) : 393 - 404
  • [2] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [3] Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
    Rogala, Pawel
    Czarnecka, Anna M.
    Cybulska-Stopa, Bozena
    Ostaszewski, Krzysztof
    Piejko, Karolina
    Zietek, Marcin
    Dziura, Robert
    Rutkowska, Ewa
    Galus, Lukasz
    Kempa-Kaminska, Natasza
    Seredynska, Joanna
    Bal, Wieslaw
    Kozak, Katarzyna
    Surus-Hyla, Anna
    Kubiatowski, Tomasz
    Kaminska-Winciorek, Grazyna
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    CANCERS, 2022, 14 (09)
  • [4] Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation
    Viatge, T.
    Mazieres, J.
    Zahi, S.
    Fajadet, P.
    Petureau, F.
    REVUE DES MALADIES RESPIRATOIRES, 2020, 37 (07) : 595 - 601
  • [5] Home anti-PD1 immunotherapy for melanoma: results of a patient and nursing satisfaction survey
    Truong, Thu Thao
    Lapassat, Marie
    Belbezier, Aude
    Leccia, Marie-Therese
    Mouret, Stephane
    Lemoigne, Aude
    Charles, Julie
    Trabelsi, Sabiha
    EUROPEAN JOURNAL OF DERMATOLOGY, 2025, 35 (01) : 31 - 37
  • [6] Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
    Amato, Carol M.
    Hintzsche, Jennifer D.
    Wells, Keith
    Applegate, Allison
    Gorden, Nicholas T.
    Vorwald, Victoria M.
    Tobin, Richard P.
    Nassar, Kelsey
    Shellman, Yiqun G.
    Kim, Jihye
    Medina, Theresa M.
    Rioth, Matthew
    Lewis, Karl D.
    McCarter, Martin D.
    Gonzalez, Rene
    Tan, Aik-Choon
    Robinson, William A.
    CANCERS, 2020, 12 (07) : 1 - 15
  • [7] Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
    Garces, Alvaro H. Ingles
    Au, Lewis
    Mason, Robert
    Thomas, Jennifer
    Larkin, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2019, 28 (08) : 695 - 708
  • [8] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [9] Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
    Huynh, Sandra
    Mortier, Laurent
    Dutriaux, Caroline
    Maubec, Eve
    Boileau, Marie
    Dereure, Olivier
    Leccia, Marie-Therese
    Arnault, Jean-Philippe
    Brunet-Possenti, Florence
    Aubin, Francois
    Dreno, Brigitte
    Beylot-Barry, Marie
    Lebbe, Celeste
    Lefevre, Wendy
    Delyon, Julie
    CANCERS, 2020, 12 (06) : 1 - 11
  • [10] Anti-PD1 role in treatment of cutaneous melanoma
    Mateus, Christine
    Libenciuc, Cristina
    Robert, Caroline
    BULLETIN DU CANCER, 2016, 103 (06) : S4 - S11